Press Releases Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal February 01, 2024 Proniras Corporation Announces National Institute on Drug Abuse (NIDA) Grant Award to Pursue Treatment for Opioid Withdrawal September 17, 2020 Accelerator Life Science Partners Launches Proniras Corporation to Support Development of Tezampanel in the Treatment of Seizure Disorders April 27, 2018 Proniras Corporation Awarded Contract Worth Up to $89.5 Million from U.S. Biomedical Advanced Research and Development Authority to Develop Tezampanel as a Medical Countermeasure for Nerve Agent-Induced Seizures April 27, 2018 In the News Proniras Corp. launches in Seattle, scores $89.5 million contract to develop new seizure drug (Geekwire.com) April 27, 2018